Get notified of page updates
This is a treatment study is for people with metastatic colorectal cancer
Clinicaltrials.gov identifier:NCT02997228
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
This is a treatment study is for people with metastatic colorectal cancer
Clinicaltrials.gov identifier:NCT02997228
Glossary on
off
About the Study
This study is no longer recruiting people.
This study is for people with colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an agent works compared with treatment using an agent alone. This study is focused on patients who are determined to be mismatch-repair deficient () or have an MSI-H diagnosis, which are commonly seen in people with .
This Study is Open To:
This study is no longer recruiting people.
This Study is NOT Open To:
This study is no longer recruiting people.